Overview

Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.

Status:
Terminated

Trial end date:
2010-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the pharmacokinetics, pharmacodynamics and safety of different doses of intravenous and oral Forodesine in children with relapsed or refractory T-cell or B-cell precursor Acute Lymphoblastic Leukaemia or T-cell Non-Hodgkin's Lymphoma. Preliminary efficacy will also be assessed.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Mundipharma Research Limited

Collaborator:

Innovative Therapies For Children with Cancer Consortium